Status:
TERMINATED
Erythropoietin and Pediatric Cardiac Surgery
Lead Sponsor:
Medical College of Wisconsin
Collaborating Sponsors:
Children's Hospital and Health System Foundation, Wisconsin
National Center for Research Resources (NCRR)
Conditions:
Congenital Heart Defect
Eligibility:
All Genders
6-18 years
Phase:
NA
Brief Summary
Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can cause damage to those organs. We hypothesize that a single dose of erythropoietin prior to the heart bypass ...
Detailed Description
Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can cause damage to those organs. A medicine already used in humans, erythropoietin, may protect the heart and b...
Eligibility Criteria
Inclusion
- Age 6 weeks to 18 years
- Requiring open heart surgery for congenital heart defect -Parents able to speak English and document informed consent -
Exclusion
- Received erythropoietin within past 30 days
- Previous adverse reaction to erythropoietin or to albumin
- History of neurological disorder -Laboratory evidence of kidney or liver dysfunction -
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00451698
Start Date
October 1 2007
End Date
December 1 2011
Last Update
November 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States, 53226